Fermeate, an industrial biotechnology startup focused on optogenetic control systems for large-scale precision fermentation, has secured a $2 million Seed funding round led by Newfund Capital, with participation from SOSV, Ajinomoto Group Ventures, Ki Tua Fund, Heuristic Capital Partners, Momentum Capital, Plug & Play, Tesserakt Ventures, and Ag Startup Engine. The new capital will be used to accelerate Fermeate’s mission of lowering production costs and helping precision fermentation products reach commercial cost parity.
The company says traditional fermentation economics have long depended on building larger facilities to reduce costs. Fermeate instead focuses on extracting more productivity from existing reactors through software-guided biological control, aiming for rapid returns with minimal infrastructure spending. According to the company, retrofit projects can deliver a payback period of under 11 months based on third-party techno-economic analyses.
At the center of Fermeate’s platform is the use of light as a biological signal. By activating or suppressing gene expression in real time, operators can dynamically steer microbial metabolism during production runs. Combined with artificial intelligence models that determine which genes to target and when, the system has reportedly improved fermentation outputs by 60% to 300% in current industrial collaborations.
A major advantage of the technology is compatibility with existing fermentation infrastructure. Fermeate says conventional stainless-steel fermenters can be upgraded into optogenetically enabled systems for less than 5% of the cost of installing new tanks, a potentially meaningful benefit for manufacturers looking to scale without major capital expenditure.
Since launch, the startup has expanded its platform to work across many of the industry’s most common microbial hosts, including conventional and non-conventional yeast strains as well as bacterial species. Fermeate is currently working with four global food and ingredient companies, reporting measurable performance gains within the first three months and protein production increases of up to 200% within six months.
Newfund Capital General Partner Henri Deshays said Fermeate’s strength lies in upgrading the world’s existing fermentation capacity rather than replacing it, describing the platform as a foundational enabling layer for the emerging bioeconomy.
Leave a Reply